InMode Ltd.’s Quiet Period Set To End Tomorrow (NASDAQ:INMD)

Share on StockTwits

InMode’s (NASDAQ:INMD) quiet period will expire on Tuesday, September 17th. InMode had issued 5,000,000 shares in its public offering on August 8th. The total size of the offering was $70,000,000 based on an initial share price of $14.00. During the company’s quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Several brokerages recently weighed in on INMD. Barclays began coverage on InMode in a research report on Tuesday, September 3rd. They set an “overweight” rating and a $27.00 price objective for the company. Canaccord Genuity began coverage on InMode in a research report on Tuesday, September 3rd. They set a “buy” rating and a $30.00 price objective for the company. UBS Group began coverage on InMode in a research report on Tuesday, September 3rd. They set a “buy” rating and a $28.00 price objective for the company. Finally, Robert W. Baird began coverage on InMode in a research report on Tuesday, September 3rd. They set an “outperform” rating and a $27.00 price objective for the company.

Shares of INMD stock opened at $28.48 on Monday. InMode has a twelve month low of $13.06 and a twelve month high of $29.24.

InMode (NASDAQ:INMD) last announced its quarterly earnings data on Tuesday, August 13th. The healthcare company reported $0.45 earnings per share for the quarter. The business had revenue of $38.80 million for the quarter. Research analysts anticipate that InMode will post 1.38 earnings per share for the current fiscal year.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.

See Also: Fundamental Analysis

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.